Immunotherapeutic for Chronic Hepatitis B Infections

An immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). It is designed to drive CD4+ and CD8+ T-cell responses against all HBV genotypes in patients of diverse genetic backgrounds. Normally, the HBV virus is eliminated through T cell dependent mechanisms but stimulating these responses in chronically infected HBV patients has been challenging due to the exhaustion of T cells directed against the virus. HepTcell has shown the potential to  break the immunotolerance characteristic of this disease and activate T cells to fight the infection.